Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022525 | 0.89 | PTPN1 (0.37) | PTPN1RAB9ANPC1ADRB2SMN1; SMN2 | |
| SCHEMBL4026179 | 0.89 | PTPN1 (0.38) | PTPN1RAB9ANPC1ADRB2SMN1; SMN2 | |
| SCHEMBL4021345 | 0.87 | PSEN1 (0.36) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL4023599 | 0.85 | PTPN1 (0.36) | PTPN1RAB9ANPC1ADRB2SMN1; SMN2 | |
| SCHEMBL4023176 | 0.85 | PTPN1 (0.33) | PTPN1RAB9ANPC1ADRB2SMN1; SMN2 | |
| SCHEMBL4024325 | 0.82 | PSEN1 (0.42) | PTPN1RAB9ANPC1ADRB2SMN1; SMN2 | |
| SCHEMBL4023360 | 0.81 | ALDH1A1 (0.32) | RAB9AMEN1TSHRKMT2AALDH1A1 | |
| SCHEMBL4192748 | 0.81 | ALDH1A1 (0.35) | RAB9ASMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL4022869 | 0.80 | PTPN1 (0.52) | PTPN1TP53ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4023946 | 0.76 | ALDH1A1 (0.41) | RAB9ASMN1; SMN2MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629377-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2009-12-08 | — | — | US | claimed |
| EP-1397356-B1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2009-05-13 | — | — | EP | claimed |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2008-07-31 | — | — | US | claimed |
| US-7351730-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2008-04-01 | — | — | US | claimed |
| US-6939886-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH (US) | 2005-09-06 | — | — | US | claimed |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH | 2004-12-30 | — | — | US | claimed |
| US-6800654-B2 | FOR TREATING CONDITIONS RESULTING FROM FIBRINOLYTIC DISORDERS SUCH AS DEEP VEIN THROMBOSIS AND CORONARY HEART DISEASE, AND PULMONARY FIBROSIS. | WYETH | 2004-10-05 | — | — | US | claimed |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-02-13 | — | — | US | claimed |
| US-7629377-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1397356-B1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7351730-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2007092207-A1 | COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185186-A1 | COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-08-09 | — | — | US | disclosed |
| US-6939886-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH | 2004-12-30 | — | — | US | disclosed |
| US-6800654-B2 | FOR TREATING CONDITIONS RESULTING FROM FIBRINOLYTIC DISORDERS SUCH AS DEEP VEIN THROMBOSIS AND CORONARY HEART DISEASE, AND PULMONARY FIBROSIS. | WYETH | 2004-10-05 | — | — | US | disclosed |
| EP-1397356-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2003000684-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185186-A1 | COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | INMT, AANAT, NAPEPLD | PTPN1 3234/4885RAB9A 4245/4885NPC1 91/4885 |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | TFPI, SERPINE1, F12 | PTPN1 658/4885RAB9A 1600/4885NPC1 1410/4885 |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | PTPN1 958/4885RAB9A 1687/4885NPC1 1599/4885 |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | PTPN1 902/4885RAB9A 1682/4885NPC1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.